Last updated on April 2016

Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid Tumors

Brief description of study

In patients with IDH1-R132X-mutant solid tumors treated with BAY1436032: 1. Determine the safety, tolerability, maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of BAY1436032; 2. Evaluate the pharmacokinetic (PK) properties and pharmacodynamic (PD) effects of BAY1436032; 3. Look for preliminary evidence of clinical efficacy in patients treated with BAY1436032; 4. Evaluate effect of standard high-fat, high calorie meal on the PK of BAY1436032.

Clinical Study Identifier: NCT02746081

Find a site near you

Start Over